TLSA
Tiziana Life Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$0.91
−6.64%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +27.7%
- EBIT
- +3.6%
- EPS
- -2.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- -9.4%
- EBIT
- -33.8%
- Net income
- -55.4%
- EPS
- -45.5%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025